R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 484-495

  Zhu, Hong ^a   Huang, Min ^a   Yang, Fan ^a   Chen, Yi ^a   Miao, Ze Hong ^a   Qian, Xu Hong ^b   Xu, Yu Fang ^b   Qin, Yu Xin ^a   Luo, Hai Bin ^a   Shen, Xu ^a   Geng, Mei Yu ^a,c   Cai, Yu Jun ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIMETHYLAMINO) 6 THIA 2 AZA BENZO [DEF] CHRYSENE 1,3 DIONE; ACLARUBICIN; ADENOSINE TRIPHOSPHATASE; AMONAFIDE; ANTINEOPLASTIC AGENT; ATM PROTEIN; CAFFEINE; CAMPTOTHECIN; CHECKPOINT KINASE RAD3; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOXANTRONE; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SARCOMA; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL DIVISION; CELL PROLIFERATION; CYTOCHROMES C; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; G2 PHASE; HUMANS; IMIDES; IN SITU NICK-END LABELING; ISOQUINOLINES; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; NAPHTHALIMIDES; POLY(ADP-RIBOSE) POLYMERASES; SARCOMA, EXPERIMENTAL; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 33847400139     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0584     Document Type: Article

References (47)

1. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
2. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;58:351-75.
3. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994;34:191-218.
4. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1998; 1400:155-71.
5. Brana MF, Ramos A. Naphthalimides as anti-cancer agents: synthesis and biological activity. Curr Med Chem Anti-Canc Agents 2001;1:237-55.
6. Scheithauer W, Dittrich C, Kornek G, et al. Phase II study of amonafide in advanced breast cancer. Breast Cancer Res Treat 1991;20:63-7.
7. Costanza ME, Berry D, Henderson IC, et al. Amonafide: an active agent in the treatment of previously untreated advanced breast cancer-a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res 1995;1: 699-704.
8. Hsiang YH, Jiang JB, Liu LF. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol Pharmacol 1989; 36:371-6.
9. Ratain MJ, Mick R, Berezin F, et al. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991; 50:573-9.
10. Ratain MJ, Mick R, Berezin F, et al. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 1993;53:2304-8.
11. Ratain MJ, Rosner G, Allen SL., et al. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol 1995;13:741-7.
12. Ratain MJ, Mick R, Janisch L, et al. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 1996;6:93-101.
13. Allen SL, Kolitz JE, Lundberg A, et al. Phase I study of amonafide + cytosine arabinoside (AraC) in patients with poor risk acute myeloid leukemia (AML). ASCO Annual Meeting Proceedings 2005;23:6602.
14. Sami SM, Dorr RT, Alberts DS, Solyom AM, Remers WA. Analogues of amonafide and azonafide with novel ring systems. J Med Chem 2000; 43:3067-73.
15. Brana MF, Cacho M, Garcia MA, et al. New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties. J Med Chem 2004;47:1391-9.
16. Li Z, Yang O, Qian X. Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: effects of intercalation, side chains, and substituent groups. Bioorg Med Chem 2005; 13:4864-70.
17. Qian X, Huang T, Wei D. Interaction of naphthyl heterocycles with DNA: effects of thiono and thio groups. J Chem Soc Perkin Trans II 2000; 715-8.
18. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
19. Miao ZH, Tang T, Zhang YX, Zhang JS, Ding J. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int J Cancer 2003;106:108-15.
20. Steinfelder HJ, Quentin I, Ritz V. A fast and sensitive technique to study the kinetics and the concentration dependencies of DNA fragmentation during drug-induced apoptosis. J Pharmacol Toxicol Methods 2000; 43:79-84.
21. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-91.
22. Lu HR, Zhu H, Huang M, et al. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase. Mol Pharmacol 2005;68:983-94.
23. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991;51:4903-8.
24. Willmore E, Frank AJ, Padget K, Tilby MJ, Austin CA. Etoposide targets topoisomerase IIα and IIβ in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol 1998;54:78-85.
25. Chaoxin H, Zhili Z, Jingui M, et al. Salvicine functions as a novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol 2006; 70:1593-601.
26. Hu T, Sage H, Hsieh TS. ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization. J Biol Chem 2002; 277:5944-51.
27. Miura K, Aminova L, Murayama Y. Fusarenon-X-induced apoptosis in HL-60 cells depends on caspase activation and cytochrome c release. Toxicology 2002; 172:103-12.
28. Yang F, Chen Y, Duan W, et al. SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Int J Cancer 2006;119:1184-93.
29. Hsiang YH, Liu LF. Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. J Biol Chem 1989;264: 9713-5.
30. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999; 59:4375-82.
31. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
32. Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II β isoform. Biochemistry 1991;30: 9953-61.
33. Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 2001;7:95-106.
34. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 2002;21:8786-803.
35. Shinoura N, Yoshida Y, Asai A, Kirino T, Hamada H. Relative level of expression of Bax and Bcl-XL determines the cellular fate of apoptosis/ necrosis induced by the overexpression of Bax. Oncogene 1999;18:5703-13.
36. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256:42-9.
37. Arnoult D, Parone P, Martinou JC, et al. Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli. J Cell Biol 2002;159: 923-9.
38. Desagher S, Osen-Sand A, Nichols A, et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 1999;144:891-901.
39. Nitiss JL, Zhou J, Rose A, et al. The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II, Biochemistry 1998;37:3078-85.
40. Kaufmann SH. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1998;1400: 195-211.
41. Kupfer G, Bodley AL, Liu LF. Involvement of intracellular ATP in cytotoxicity of topoisomerase II-targetting antitumor drugs. NCI Monogr 1987; 37-40.
42. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006;66:4863-71.
43. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001; 11: 71-7.
44. Pauklin S, Kristjuhan A, Maimets T, Jaks V. ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress. Biochem Biophys Res Commun 2005;334:386-94.
45. Yao SL, Akhtar AJ, McKenna KA, et al. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med 1996;2:1140-3.
46. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-65.
47. Traganos F, Kapuscinski J, Gong J, et al. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells. Cancer Res 1993;53:4613-8.